Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag Ord (OP:BAYZF)

55.00 +0.81 (+1.49%)

Streaming Delayed Price Updated: 2:58 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag Ord

< Previous 1 2 3 4 Next >

OTC Markets Group Welcomes Bayer AG to OTCQX

May 23, 2025

From OTC Markets

Via GlobeNewswire

Bayer Shares Fall 7% As US Court Reconsiders Monsanto PCB Exposure Case ↗

October 09, 2024

German life sciences giant Bayer saw its shares drop by over 7% on Wednesday following a US court’s decision to review a case against Monsanto, a subsidiary acquired by Bayer in 2018.

Via Talk Markets

Futures Rally Fizzles As Dollar, Yields And Oil Slump ↗

August 17, 2024

US equity futures erased earlier gains and were trading with modest losses as the dollar, oil, and yields all slumped entering the US session.

Via Talk Markets

Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer ↗

July 25, 2024

Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe.

Via Benzinga

Topics Lawsuit

Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M ↗

June 05, 2024

Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation.

Via Benzinga

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗

May 24, 2024

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

Via Benzinga

Topics Data Breach

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval ↗

May 17, 2024

Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.

Via Benzinga

Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned ↗

May 02, 2024

Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs...

Via Benzinga

Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant ↗

March 19, 2024

Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential...

Via Benzinga

German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits ↗

March 14, 2024

Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications.

Via Benzinga

Topics Bankruptcy Lawsuit

Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges ↗

March 05, 2024

Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024.

Via Benzinga

What's Going On With BridgeBio Pharma Stock On Monday? ↗

March 04, 2024

BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.

Via Benzinga

Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial ↗

January 30, 2024

Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.

Via Benzinga

Topics Lawsuit

Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout ↗

January 29, 2024

"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.

Via Benzinga

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial ↗

January 08, 2024

Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)

Via Benzinga

Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial ↗

January 04, 2024

Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.

Via Benzinga

Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak ↗

December 26, 2023

In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin...

Via Benzinga

Topics Lawsuit

ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US ↗

December 19, 2023

With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience...

Via Benzinga

Topics Climate Change

Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss ↗

December 06, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion ↗

December 04, 2023

The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts

Via Benzinga

Topics Lawsuit

German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks ↗

November 24, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about...

Via Benzinga

Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence ↗

November 20, 2023

Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details ↗

November 20, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits ↗

November 17, 2023

The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products...

Via Benzinga

Topics Lawsuit

Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss ↗

November 08, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced

Via Benzinga

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗

November 01, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗

August 28, 2023

Reuters

Via Benzinga

German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗

August 28, 2023

Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bayer Ag Ord (OP:BAYZF)

All News about Bayer Ag Ord

Starting at $3.75/week.

Subscribe Today